Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.

about

Research on kidney and mineral metabolism in Japan: past, present, and future.Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis.

P2860

Q38779344-C1023E42-A4AA-4985-ACDE-F73FB5CEB8A5 Q47975335-EA1B109F-6219-4E99-92B8-894C8C030175

P2860

Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.

Item

http://www.wikidata.org/entity/Q40451914

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Bixalomer in Hyperphosphatemic ...... sis: Phase 3 Randomized Trial.

@en

type

Item

label

Bixalomer in Hyperphosphatemic ...... sis: Phase 3 Randomized Trial.

@en

prefLabel

Bixalomer in Hyperphosphatemic ...... sis: Phase 3 Randomized Trial.

@en

P1476

Bixalomer in Hyperphosphatemic ...... sis: Phase 3 Randomized Trial.

@en

P2093

Chisato Kameoka

http://www.w3.org/2001/XMLSchema#string

Hideki Origasa

http://www.w3.org/2001/XMLSchema#string

Kentarou Kuroishi

http://www.w3.org/2001/XMLSchema#string

Tadao Akizawa

http://www.w3.org/2001/XMLSchema#string

Yusuke Yamaguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of concurrent complications of CKD by 2 risk categorization systems.

Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Effects of phosphate binders in moderate CKD

Risks of chronic metabolic acidosis in patients with chronic kidney disease.

Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial

Next-generation phosphate binders: focus on iron-based binders.

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.

P304

588-597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1744-9987.12461

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Junko Tsukada

P577

2016-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27896908

http://www.w3.org/2001/XMLSchema#string

P921

renal dialysis

phase III clinical trial

Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.

about

P2860

P2860

Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921